Skip to main content
. 2020 Dec 15;8(4):E877–E886. doi: 10.9778/cmajo.20200055

Table 1:

Baseline characteristics of patients included in the base cohort

Characteristic Group; no. (%) of patients*
DOAC
n = 142 336
Warfarin
n = 113 515
Age, mean ± SE, yr 74.7 ± 1.3 75.8 ± 0.9
Sex, male 76 572 (53.8) 61 200 (53.9)
Year of base cohort entry
2009–2010 302 (0.2) 19 093 (16.8)
2011–2012 29 959 (21.0) 40 022 (35.3)
2013–2014 56 574 (39.7) 37 457 (33.0)
2015–2016 55 420 (38.9) 16 943 (14.9)
DOAC received at study entry
Dabigatran 44 639 (31.4)
 110 mg twice daily 22 296 (49.9)
 150 mg twice daily 20 409 (45.7)
 Other 1934 (4.3)
Rivaroxaban 55 131 (38.7)
 15 mg once daily 13 473 (24.4)
 20 mg once daily 39 005 (70.7)
 Other 2653 (4.8)
Apixaban 42 566 (29.9)
 2.5 mg twice daily 14 250 (33.5)
 5 mg twice daily 26 504 (62.3)
 Other 1812 (4.3)
Treatment switches 6826 (4.8) 32 780 (28.9)
Length of follow-up, mean ± SE, d 624.7 ± 67.1 1015.2 ± 96.1
Medical diagnoses
Congestive heart failure 33 558 (23.6) 38 824 (34.2)
Hypertension 106 256 (74.6) 90 957 (80.1)
Diabetes 42 813 (30.1) 41 327 (36.4)
Stroke 23 540 (16.5) 23 396 (20.6)
Transient ischemic attack 7314 (5.1) 6788 (6.0)
Chronic kidney injury 14 345 (10.1) 20 470 (18.0)
Acute kidney injury 5798 (4.1) 9505 (8.4)
Liver disease 5739 (4.0) 4270 (3.8)
Cancer 15 039 (10.6) 14 606 (12.9)
Chronic obstructive pulmonary disease 38 010 (26.7) 38 864 (34.2)
Coronary atherosclerosis 64 340 (45.2) 57 846 (51.0)
Myocardial infarction 19 978 (14.0) 21 914 (19.3)
Peripheral vascular disease 17 873 (12.6) 20 668 (18.2)
Prior bleeding 9208 (6.5) 11 942 (10.5)
Dementia 14 866 (10.4) 12 018 (10.6)

Note: DOAC = direct oral anticoagulant, SE = standard error.

*

Except where noted otherwise.

Inconsistencies in total number of patients for categoric variables are due to deletion of small cells for confidentiality reasons.